10-Q: Cardiff Oncology Q3 Loss Narrows, Onvansertib Shows Promise

Cardiff Oncology reports a reduced net loss in Q3 2025, driven by decreased R&D expenses, while its lead asset onvansertib continues to show promising clinical trial results in multiple cancer indications.

Summary

• Net loss for the three months ended September 30, 2025, was $11.3 million, an improvement from $11.9 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $38.6 million, compared to $33.6 million for the same period in 2024.
• Research and development expenses decreased by $1.4 million in Q3 2025 compared to Q3 2024, primarily due to a reduction in clinical trial and preclinical activities.
• Research and development expenses increased by $3.1 million for the nine months ended September 30, 2025, compared to 2024, mainly due to costs associated with the CRDF-004 clinical trial and other clinical programs.
• Selling, general and administrative expenses increased by $0.8 million in Q3 2025 compared to Q3 2024, primarily due to an employee severance agreement.
• Selling, general and administrative expenses increased by $1.8 million for the nine months ended September 30, 2025, compared to 2024, driven by severance, strategic advisory services, and patent fees.
• Cash, cash equivalents, and short-term investments totaled $60.6 million as of September 30, 2025.
• The company believes it has sufficient cash to meet its funding requirements for at least the next 12 months and expects its capital resources to fund operations into the first quarter of 2027.
• The CRDF-004 Phase 2 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC) showed a confirmed Objective Response Rate (ORR) of 49% for the onvansertib 30mg + SoC arm and 42% for the onvansertib 20mg + SoC arm, compared to 30% for SoC alone (data cut-off July 8, 2025).
• An investigator-initiated Phase 1b/2 trial of onvansertib in combination with NALIRIFOX for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) is open for enrollment.
• A Phase 1b investigator-initiated trial of onvansertib in combination with paclitaxel for metastatic triple negative breast cancer (mTNBC) completed enrollment and presented positive data in June 2025, demonstrating a 40% ORR at the recommended Phase 2 dose (n=10).

Sentiment

Score: 7

Explanation: The company reported a reduced net loss for the quarter and presented positive clinical data for its lead asset, onvansertib, across multiple cancer indications, particularly in RAS-mutated mCRC and mTNBC. The cash runway is projected into Q1 2027, providing a reasonable operational window. However, the company continues to incur significant losses and will require substantial additional capital in the future, posing a long-term financial risk.

Positives

• Net loss for Q3 2025 decreased to $11.3 million from $11.9 million in Q3 2024, indicating improved quarterly financial performance.
• The CRDF-004 Phase 2 trial in RAS-mutated mCRC demonstrated significantly higher confirmed Objective Response Rates (ORR) with onvansertib combinations (49% for 30mg + SoC and 42% for 20mg + SoC) compared to standard-of-care alone (30%).
• Onvansertib in combination with chemo/bevacizumab was well-tolerated in the CRDF-004 trial, with no major or unexpected toxicities observed.
• Positive data from the Phase 1b mTNBC trial, presented in June 2025, showed a 40% ORR at the recommended Phase 2 dose, supporting further exploration of the combination.
• The company maintains a strong liquidity position with $60.6 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
• Current capital resources are projected to be sufficient to fund operations into the first quarter of 2027, providing a substantial runway.
• Expansion of the clinical pipeline with an investigator-initiated mPDAC trial combining onvansertib with NALIRIFOX, which is now open for enrollment.

Negatives

• Net loss for the nine months ended September 30, 2025, increased to $38.6 million from $33.6 million in the prior year, indicating a higher burn rate over the longer term.
• Total revenues decreased for both the three-month ($0.1 million vs. $0.2 million) and nine-month ($0.4 million vs. $0.5 million) periods compared to the prior year.
• Cash and cash equivalents significantly decreased from $51.470 million at December 31, 2024, to $10.135 million at September 30, 2025.
• Working capital decreased from $81.6 million at December 31, 2024, to $47.1 million at September 30, 2025.
• The company continues to experience negative operating cash flows, with $32.0 million used in operating activities for the nine months ended September 30, 2025.
• Expects to continue incurring losses and will require additional capital for the foreseeable future to advance clinical trial programs and support operations.
• Potential for additional stockholder dilution if future funding is secured through the issuance of equity securities.

Risks

• The company has incurred net losses since its inception and has negative operating cash flows, indicating a reliance on external funding.
• Additional capital will be required to further advance clinical trial programs and support other operations, and there is no certainty that such funding will be available on acceptable terms or at all.
• Raising additional funds by issuing equity securities may lead to further dilution for existing stockholders.
• Drug development efforts are in early stages, and there is a high risk of completion due to uncertainties involved in clinical testing, regulatory approval processes, and competition from other organizations with greater resources.
• Inadequate funding for government agencies like the FDA and SEC could hinder their ability to review and approve new products or perform normal business functions, potentially delaying the company's drug development and commercialization efforts.
• Government shutdowns or global health concerns could significantly impact the FDA's ability to timely review and process regulatory submissions, adversely affecting the business.

Future Outlook

The company expects to continue incurring losses and requiring additional capital for the foreseeable future to further advance its clinical trial programs and support other operations. There is no certainty that additional funding will be available on acceptable terms, or at all, and any equity raises could lead to stockholder dilution. Contingent upon the results of the CRDF-004 trial, the company plans to initiate CRDF-005, a Phase 3 randomized trial with registrational intent. Current capital resources are projected to fund operations into the first quarter of 2027.

Management Comments

• "We believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of these financial statements."
• "For the foreseeable future, we expect to continue to incur losses and require additional capital to further advance our clinical trial programs and support our other operations."
• "We cannot be certain that additional funding will be available on acceptable terms, or at all."
• "To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience additional dilution."
• "Management believes that there are no claims against the Company, which could result in a material adverse effect on the Company’s business or financial condition."
• "Our disclosure controls and procedures were effective as of September 30, 2025, to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms."

Industry Context

Cardiff Oncology operates in the highly competitive and rapidly evolving clinical-stage biotechnology sector, with a specialized focus on oncology. The company's strategy of targeting tumor vulnerabilities through Polo-like Kinase 1 (PLK1) inhibition and combining its lead asset, onvansertib, with standard-of-care therapeutics aligns with broader industry trends aimed at overcoming treatment resistance and improving patient outcomes. The focus on indications such as RAS-mutated mCRC, mPDAC, SCLC, and mTNBC addresses significant unmet medical needs, a common strategic imperative for biotech firms. The collaboration with Pfizer Ignite for the CRDF-004 trial exemplifies the industry's trend towards partnerships to leverage expertise and resources in complex drug development. The FDA's approval of NALIRIFOX for mPDAC in February 2024 also highlights the dynamic regulatory landscape, requiring companies like Cardiff Oncology to adapt their clinical strategies to incorporate new standard-of-care options.

Legal Proceedings

• Management believes there are no claims against the company that could result in a material adverse effect on its business or financial condition.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises, but positive clinical trial data could enhance long-term value.
• Employees are impacted by ongoing workforce adjustments, including key hires in R&D and clinical operations, and stock-based compensation.
• Future patients could benefit from onvansertib as a new treatment option for various cancers with high unmet medical needs, given the promising clinical trial results.
• Creditors and suppliers may monitor the company's continued negative operating cash flows and reliance on future capital raises, although current liquidity is deemed sufficient for the near term.
• Regulatory authorities will continue to be engaged through ongoing clinical trials and future registrational trials, with potential impacts from government funding and operational disruptions.

Next Steps

• Initiate CRDF-005, a Phase 3 randomized trial with registrational intent, contingent upon the results of CRDF-004.
• Continue enrollment for the investigator-initiated mPDAC Phase 1b/2 trial of onvansertib in combination with NALIRIFOX.
• Continue enrollment for the Phase 2 investigator-initiated trial of onvansertib monotherapy in relapsed SCLC.
• Evaluate the impact of ASU 2023-09 (Improvements to Income Tax Disclosures) on financial statement disclosures.
• Evaluate the impact of ASU 2024-03 (Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures) on financial statement disclosures.

Key Dates

Recommendation

While the clinical trial data for onvansertib, particularly the improved Objective Response Rates in RAS-mutated mCRC and positive signals in mTNBC, are highly encouraging and suggest strong therapeutic potential, the company remains in a clinical-stage with significant ongoing losses. The projected cash runway into Q1 2027 provides a buffer, but the explicit need for future capital raises and the inherent risks of drug development, including regulatory hurdles and competition, warrant a cautious approach. The stock has upside potential if future trials confirm efficacy and lead to approval, but the financial profile and early stage of development suggest a 'Hold' for investors awaiting further de-risking through advanced clinical milestones and clearer paths to commercialization.

Keywords

Oncology, Biotechnology, Clinical-stage, PLK1 inhibitor, Onvansertib, RAS-mutated mCRC, Metastatic colorectal cancer, mPDAC, Pancreatic ductal adenocarcinoma, SCLC, Small cell lung cancer, mTNBC, Triple negative breast cancer, Clinical trials, Drug development, SEC filing, CRDF